STOCK TITAN
  1. Home
  2. Sec-filings
  3. ZYME
  4. [SCHEDULE 13G/A] Zymeworks Inc. SEC Filing

[SCHEDULE 13G/A] Zymeworks Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ZYME logo
Zymeworks

NASDAQ:ZYME

ZYME Rankings

#2515 Ranked by Market Cap
N/A Ranked by Dividends

ZYME Latest News

Oct 9, 2025
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
Sep 2, 2025
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
Aug 19, 2025
Zymeworks Announces Participation in Upcoming Investor Conferences
Aug 11, 2025
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
Aug 7, 2025
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

ZYME Latest SEC Filings

Sep 2, 2025
[8-K] Zymeworks Inc. Reports Material Event
Aug 14, 2025
[SCHEDULE 13G/A] Zymeworks Inc. SEC Filing
Aug 12, 2025
[Form 4] Zymeworks Inc. Insider Trading Activity
Aug 12, 2025
[Form 4] Zymeworks Inc. Insider Trading Activity
Aug 12, 2025
[Form 3] Zymeworks Inc. Initial Statement of Beneficial Ownership

ZYME Stock Data

1.28B
73.28M
0.8%
101.5%
9.09%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIDDLETOWN